Kathleen Boyle

Kathleen Boyle serves as VP of Research Operations at Walking Fish Therapeutics, with roles spanning R&D Strategy, Operations, Program Management and Business Development. Involved early in the company foundation, she served as a Scientific Research Lead for key programs and expanded into a role in Corporate Development and Operations.

Prior to joining the founding team at Walking Fish, Ms. Boyle was an early key member of the founding scientific team at Nurix Therapeutics in 2012. There she was involved in the early development and execution of the company's development plan as part of a small team – including senior venture partners from Third Rock and The Column Group. As the company grew and entered into a major collaboration with Celgene, Ms. Boyle served as both Discovery Lead and Program Lead for numerous key strategic programs, managing cross-functional teams and guiding lead programs, both internal and partnered. She is a co-inventor of Nurix’s Cbl-b inhibitor scaffold for NX-1607 (oral administration) and NX-0255 (DeTIL-0255; Adoptive Cell Therapy) and co-discoverer of the first “Molecular Glue” compound enhancing binding of a ligase to its substrate (Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction” Nature Commun 2019 Mar 29;10(1):1402). Ms. Boyle holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley. Upon graduating in 2003, Ms. Boyle accepted a unique opportunity to work in the lab of Dr. Bruce Ames at the UCSF Benioff Children’s Hospital Oakland Research Institute. In 2007, Ms. Boyle left academia and joined Five Prime Therapeutics where she drove screening campaigns and identified therapeutic leads as a project lead in large-scale collaborations with major pharmaceutical firms, including GlaxoSmithKline and Pfizer.